GI / HepatologyInfectious Disease
Clostridioides difficile Colitis
NICE NG199 / IDSA — recognition, severity stratification, antibiotic choice (vancomycin / fidaxomicin), recurrence prevention.
Source: NICE NG199 (2021); IDSA/SHEA 2021
Step 1 of ~6
info
Recognise + Investigate
Diarrhoea (≥3 unformed stools/24h) + risk factors: recent antibiotics (cephalosporins, fluoroquinolones, clindamycin, broad-spectrum β-lactams), age >65, hospitalisation, PPI, immunosuppression. Send stool: C diff toxin (EIA + GDH) + PCR. Isolate (single room, contact precautions). Bloods: FBC, U&E, CRP, lactate, albumin.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Vancomycin · Glycopeptide antibiotic
- Fidaxomicin · Macrocyclic antibiotic (narrow-spectrum)
- Vancomycin (Orthopaedic Bone and Joint Infections) · Glycopeptide Antibiotic
- Vancomycin (Paediatric) · Glycopeptide Antibiotic — MRSA / Severe Gram-Positive Infections in Children
- Vancomycin (Burns — MRSA) · Antibiotic — Glycopeptide
- Linezolid (Burns — Vancomycin-Resistant/Refractory MRSA) · Antibiotic — Oxazolidinone
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Acute Severe Ulcerative Colitis · BSG 2019; ECCO 2022
Decision support only. Always apply local guidelines and clinical judgement.